Shots:

• The P-III (IMROZ) clinical trial evaluates Sarclisa (10mg/kg, IV, qw) + VRd SoC (bortezomib, lenalidomide & dexamethasone) vs VRd alone in patients (n=484) with transplant-ineligible MM across 104 centers in 21 countries
• The 1EP of the study includes PFS & the 2EPs include safety, PK, immunogenicity, CRR, minimal residual disease negativity rate for patients with a CR, OS, partial response, ORR, DoR, PFS on next line of therapy/MRD status, and time to progression/first & best response
• The results from the study depicted an improvement in PFS with Sarclisa vs VRd alone. Additionally, Sarclisa has previously been approved in over 50 countries incl. the US & EU in combination with pomalidomide & dexamethasone for RRMM patients

Ref: Globenewswire | Image: Sanofi 

Related News:- Sanofi Presents Results of Sarclisa (isatuximab) in P-III (IKEMA) Trial for Relapsed Multiple Myeloma at COMy 2022

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com